Developer docs
API playgroundTry for free, no card

Search company profiles

H. C. Wainwright & Co.

Full company profile

uuid00021cf

Namestring
H. C. Wainwright & Co.
Legal namestring
H.C. Wainwright & Co., LLC
Websiteurl
hcwco.com
Company typeenum
Private
Founded yearint
1868
Descriptiontext

H.C. Wainwright & Co. is a privately-held, FINRA- and SIPC-registered broker-dealer and investment bank founded in 1868 in Boston and now headquartered at 430 Park Avenue, New York. The firm operates an integrated platform across five service lines: Investment Banking (with a specialized PIPE / Registered Direct placement franchise ranked #1 cumulatively since 1998 by Sagient Research Systems / PlacementTracker), Advisory (M&A and strategic financing), Research (equity coverage spanning healthcare/biotech, technology, cryptocurrency & FinTech, metals & mining, and clean tech), Sales & Trading (block trading and liquidity provision in illiquid small/mid-cap equities), and Corporate Access (conferences, roadshows, one-on-one meetings). The firm serves small and mid-size growth companies as its primary customer segment, with institutional investors (hedge funds, asset managers, family offices) as a secondary segment reached through the sales & trading and corporate access channels.

The firm has no proprietary software products or disclosed technology platform; its core "technology" is the integrated workflow of research publication, sales-and-trading desk, and placement execution, supported by standard broker-dealer compliance and trading infrastructure. Approximately 11–50 employees serve a coverage universe of more than 500 companies, with lean staffing reflecting the boutique model.

H.C. Wainwright's revenue mechanics are predominantly transaction-based: placement fees on PIPE and RD offerings (typically 5–8% of gross proceeds per disclosed commentary), advisory fees on M&A and capital-markets mandates, and sales & trading commissions. Pricing is not publicly disclosed and varies by deal size and complexity. Distribution is sales-led, with dedicated institutional sales coverage, an annual global investment conference, and ongoing corporate access events. Recent leadership changes in 2025 (CEO Mark E. Kaplan, CFO Scott Gray, Executive Vice Chairman Mark Viklund) and 2024–2026 senior hires in healthcare investment banking and healthcare equities sales indicate active franchise reinvestment at the senior level.

Short descriptiontext

H.C. Wainwright & Co. is a privately-held, FINRA/SIPC-registered broker-dealer and boutique investment bank founded in 1868, headquartered in New York, serving small and mid-size growth companies across healthcare, technology, crypto, metals & mining, and clean tech with PIPE/RD placement, advisory, equity research, sales & trading, and corporate access services, ranked #1 in PIPE/RD placement since 1998.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
investment banking services, PIPE placements, equity research, sales and trading, corporate access
Industry3 codes
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory
SECONDARYFSAEACAG
Independent Broker-Dealer / Registered Representative Networks
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Securities Brokerage (Retail & Institutional)
SECONDARYFSAEAGAF
Fairness Opinions & Independent Board Advice
NAICS code2 codes
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Investment Banking
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Investment Banking - PIPE and Registered Direct Offerings
TypeTransaction Fee
Description

H.C. Wainwright serves as exclusive placement agent for equity offerings including PIPE (Private Investment in Public Equity) and RD (Registered Direct) transactions, generating fees from transaction structuring and placement services.

hcwco.com
2Research Services
TypeSubscription Recurring
Description

The firm generates revenue through equity research coverage of healthcare, technology, metals & mining, cryptocurrency, and clean technology sectors, supporting investment banking activities and client visibility.

hcwco.com
3Advisory Services
TypeProfessional Services
Description

Strategic advisory services for mergers, acquisitions, and capital markets transactions for small and mid-size market companies.

hcwco.com
4Sales & Trading
TypeTransaction Fee
Description

Sales and trading services specializing in block trading and providing liquidity in illiquid equities, generating commissions and transaction fees.

hcwco.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Transaction-based investment banking fees
ModelOtherBilling cadencePay-as-you-go
Notes

Fees are structured on a per-transaction basis for PIPE and RD offerings, with percentage-based placement fees typically ranging from 5-8% of gross proceeds, varying by deal size and complexity.

hcwco.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

H. C. Wainwright & Co. is a privately-held investment bank founded in 1868 and headquartered in New York, providing investment banking, advisory, equity research, sales & trading, and corporate access services. The firm specializes in PIPE (Private Investment in Public Equity) and RD (Registered Direct) financings, serving small and mid-size growth companies alongside institutional investors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Ranked #1 Placement Agent in PIPE and RD transactions cumulatively since 1998
+1 more record
Product overview1 text field

H.C. Wainwright & Co. is a financial services firm offering a unified suite of investment banking, advisory, research, sales & trading, and corporate access services. The firm specializes in capital raising through PIPE and registered direct offerings, with equity research coverage spanning healthcare (biotech, pharma), technology, cryptocurrency, clean technology, and metals & mining sectors. The investment banking service serves as the core revenue driver, supported by advisory capabilities and an extensive distribution network through sales & trading and corporate access.

Product and service5 records
1Investment Banking
CategoryCapital Markets
2Advisory Services
CategoryFinancial Advisory
3Equity Research
CategoryResearch
4Sales & Trading
CategoryBrokerage
5Corporate Access
CategoryInvestor Relations
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A boutique investment bank and research firm focused on healthcare, technology, and consumer sectors — directly competes with H.C. Wainwright in PIPE placements, equity research coverage, and small-cap advisory mandates.

TypeEmerging player
Description

A boutique investment bank providing capital markets services, research, and advisory to small/mid-cap growth companies — overlaps with HCW's PIPE/RD placement and research sponsorship business, particularly in technology and growth sectors.

TypeEmerging player
Description

A newer boutique investment bank emphasizing small/mid-cap advisory and capital markets — competes for the same issuer client base as HCW, with overlapping research and placement capabilities, though with a smaller institutional footprint.

TypeDirect peer
Description

A boutique investment bank focused on healthcare, technology, and small-cap advisory, with HCW hiring multiple senior staff from Chardan (Director of Research David Lenchus, Head of Healthcare Research Andrew Fein) — making it a closely comparable talent and business model competitor.

TypeBroad incumbent
Description

A larger diversified financial services firm offering investment banking, research, wealth management, and capital markets — competes with HCW in small/mid-cap advisory and research, with broader product capabilities and balance sheet access.

TypeDirect peer
Description

A Minneapolis-based boutique investment bank with research and advisory focus on small/mid-cap growth companies — competes in similar sectors with HCW for equity research sponsorship, capital raising, and corporate access mandates.

TypeDirect peer
Description

A full-service broker-dealer and investment bank with research and capital markets focus on small/mid-cap companies — directly comparable to HCW in sector-specialized equity research and PIPE/placement activity.

TypeDirect peer
Description

A diversified financial services firm with substantial equity research, investment banking, and sales/trading operations covering small/mid-cap biotech and growth companies — a key competitor for HCW's healthcare research and placement mandates.

TypeDirect peer
Description

A boutique investment bank historically focused on small/mid-cap healthcare and technology equity financing — direct competitor in PIPE and registered direct offerings, with multiple HCW analysts having previously worked at Rodman.

TypeDirect peer
Description

A boutique investment bank specializing in small and mid-cap public companies across similar sectors to H.C. Wainwright, with comparable PIPE/placement, equity research, and advisory services — competing head-to-head in the same healthcare and growth-company segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment13 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

H. C. Wainwright & Co.

Investment Bankinghcwco.com

H.C. Wainwright & Co. is a privately-held, FINRA/SIPC-registered broker-dealer and boutique investment bank founded in 1868, headquartered in New York, serving small and mid-size growth companies across healthcare, technology, crypto, metals & mining, and clean tech with PIPE/RD placement, advisory, equity research, sales & trading, and corporate access services, ranked #1 in PIPE/RD placement since 1998.

What H. C. Wainwright & Co. does

H.C. Wainwright & Co. is a privately-held, FINRA- and SIPC-registered broker-dealer and investment bank founded in 1868 in Boston and now headquartered at 430 Park Avenue, New York. The firm operates an integrated platform across five service lines: Investment Banking (with a specialized PIPE / Registered Direct placement franchise ranked #1 cumulatively since 1998 by Sagient Research Systems / PlacementTracker), Advisory (M&A and strategic financing), Research (equity coverage spanning healthcare/biotech, technology, cryptocurrency & FinTech, metals & mining, and clean tech), Sales & Trading (block trading and liquidity provision in illiquid small/mid-cap equities), and Corporate Access (conferences, roadshows, one-on-one meetings). The firm serves small and mid-size growth companies as its primary customer segment, with institutional investors (hedge funds, asset managers, family offices) as a secondary segment reached through the sales & trading and corporate access channels.

The firm has no proprietary software products or disclosed technology platform; its core "technology" is the integrated workflow of research publication, sales-and-trading desk, and placement execution, supported by standard broker-dealer compliance and trading infrastructure. Approximately 11–50 employees serve a coverage universe of more than 500 companies, with lean staffing reflecting the boutique model.

H.C. Wainwright's revenue mechanics are predominantly transaction-based: placement fees on PIPE and RD offerings (typically 5–8% of gross proceeds per disclosed commentary), advisory fees on M&A and capital-markets mandates, and sales & trading commissions. Pricing is not publicly disclosed and varies by deal size and complexity. Distribution is sales-led, with dedicated institutional sales coverage, an annual global investment conference, and ongoing corporate access events. Recent leadership changes in 2025 (CEO Mark E. Kaplan, CFO Scott Gray, Executive Vice Chairman Mark Viklund) and 2024–2026 senior hires in healthcare investment banking and healthcare equities sales indicate active franchise reinvestment at the senior level.

H. C. Wainwright & Co. firmographics

Firmographics
Name
H. C. Wainwright & Co.
Legal name
H.C. Wainwright & Co., LLC
Website
https://hcwco.com
Company type
Private
Founded year
1868
Operating status
Operating
Headcount range
101–250 employees
Short description
H.C. Wainwright & Co. is a privately-held, FINRA/SIPC-registered broker-dealer and boutique investment bank founded in 1868, headquartered in New York, serving small and mid-size growth companies across healthcare, technology, crypto, metals & mining, and clean tech with PIPE/RD placement, advisory, equity research, sales & trading, and corporate access services, ranked #1 in PIPE/RD placement since 1998.
Ownership category
akta.pro rank

H. C. Wainwright & Co. industry classification

Industry
Product category
Investment Banking
NAICS
Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523), Portfolio Management and Investment Advice (52394)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory
SECONDARYFSAEACAG
Independent Broker-Dealer / Registered Representative Networks
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Securities Brokerage (Retail & Institutional)
SECONDARYFSAEAGAF
Fairness Opinions & Independent Board Advice

Keywords

  • Investment banking services
  • PIPE placements
  • Equity research
  • Sales and trading
  • Corporate access

Where H. C. Wainwright & Co. is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

H. C. Wainwright & Co. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Investment Banking - PIPE and Registered Direct Offerings: H.C. Wainwright serves as exclusive placement agent for equity offerings including PIPE (Private Investment in Public Equity) and RD (Registered Direct) transactions, generating fees from transaction structuring and placement services.
  2. Research Services: The firm generates revenue through equity research coverage of healthcare, technology, metals & mining, cryptocurrency, and clean technology sectors, supporting investment banking activities and client visibility.
  3. Advisory Services: Strategic advisory services for mergers, acquisitions, and capital markets transactions for small and mid-size market companies.
  4. Sales & Trading: Sales and trading services specializing in block trading and providing liquidity in illiquid equities, generating commissions and transaction fees.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goTransaction-based investment banking fees

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

H. C. Wainwright & Co. product offering

Product offering

Core offering

H. C. Wainwright & Co. is a privately-held investment bank founded in 1868 and headquartered in New York, providing investment banking, advisory, equity research, sales & trading, and corporate access services. The firm specializes in PIPE (Private Investment in Public Equity) and RD (Registered Direct) financings, serving small and mid-size growth companies alongside institutional investors.

Product overview

H.C. Wainwright & Co. is a financial services firm offering a unified suite of investment banking, advisory, research, sales & trading, and corporate access services. The firm specializes in capital raising through PIPE and registered direct offerings, with equity research coverage spanning healthcare (biotech, pharma), technology, cryptocurrency, clean technology, and metals & mining sectors. The investment banking service serves as the core revenue driver, supported by advisory capabilities and an extensive distribution network through sales & trading and corporate access.

Differentiator

Problem solved

Functional benefit

Products and services

  • Investment Banking
  • Advisory Services
  • Equity Research
  • Sales & Trading
  • Corporate Access

Quantifiable outcome

  • Ranked #1 Placement Agent in PIPE and RD transactions cumulatively since 1998
  • +1 more outcomes

Companies that use H. C. Wainwright & Co.

Customer profile

Segments2 records

Ideal customer profiles2 records

H. C. Wainwright & Co. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

H. C. Wainwright & Co. partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

H. C. Wainwright & Co. competitors and assessment

Company assessment

Direct peers

  • Maxim Group: A boutique investment bank and research firm focused on healthcare, technology, and consumer sectors — directly competes with H.C. Wainwright in PIPE placements, equity research coverage, and small-cap advisory mandates.
  • Chardan Capital Markets: A boutique investment bank focused on healthcare, technology, and small-cap advisory, with HCW hiring multiple senior staff from Chardan (Director of Research David Lenchus, Head of Healthcare Research Andrew Fein) — making it a closely comparable talent and business model competitor.
  • Lake Street Capital Markets: A Minneapolis-based boutique investment bank with research and advisory focus on small/mid-cap growth companies — competes in similar sectors with HCW for equity research sponsorship, capital raising, and corporate access mandates.
  • Aegis Capital Corp. A full-service broker-dealer and investment bank with research and capital markets focus on small/mid-cap companies — directly comparable to HCW in sector-specialized equity research and PIPE/placement activity.
  • Cantor Fitzgerald: A diversified financial services firm with substantial equity research, investment banking, and sales/trading operations covering small/mid-cap biotech and growth companies — a key competitor for HCW's healthcare research and placement mandates.
  • Rodman & Renshaw: A boutique investment bank historically focused on small/mid-cap healthcare and technology equity financing — direct competitor in PIPE and registered direct offerings, with multiple HCW analysts having previously worked at Rodman.
  • Roth Capital Partners: A boutique investment bank specializing in small and mid-cap public companies across similar sectors to H.C. Wainwright, with comparable PIPE/placement, equity research, and advisory services — competing head-to-head in the same healthcare and growth-company segments.

Emerging players

  • ThinkEquity: A boutique investment bank providing capital markets services, research, and advisory to small/mid-cap growth companies — overlaps with HCW's PIPE/RD placement and research sponsorship business, particularly in technology and growth sectors.
  • EF Hutton: A newer boutique investment bank emphasizing small/mid-cap advisory and capital markets — competes for the same issuer client base as HCW, with overlapping research and placement capabilities, though with a smaller institutional footprint.

Broad incumbents

  • B. Riley Financial: A larger diversified financial services firm offering investment banking, research, wealth management, and capital markets — competes with HCW in small/mid-cap advisory and research, with broader product capabilities and balance sheet access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

H. C. Wainwright & Co. social profiles

Digital presence

H. C. Wainwright & Co. compliance and trust

Trust signal

Compliance3 records

H. C. Wainwright & Co. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

H. C. Wainwright & Co. leadership team

Management profile

Number of profiles

H. C. Wainwright & Co. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

H. C. Wainwright & Co. M&A and investment

M&A and investment

M&A

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about H. C. Wainwright & Co.

What does H. C. Wainwright & Co. do?

H. C. Wainwright & Co. is a privately-held investment bank founded in 1868 and headquartered in New York, providing investment banking, advisory, equity research, sales & trading, and corporate access services. The firm specializes in PIPE (Private Investment in Public Equity) and RD (Registered Direct) financings, serving small and mid-size growth companies alongside institutional investors.

Is H. C. Wainwright & Co. a public or private company?

H. C. Wainwright & Co. is a private company. It is classified as management employee owned and is currently operating.

When was H. C. Wainwright & Co. founded?

H. C. Wainwright & Co. was founded in 1868. It employs 101 to 250 people.

Where is H. C. Wainwright & Co. based?

H. C. Wainwright & Co. is headquartered in New York, United States, in the North America region.

How does H. C. Wainwright & Co. make money?

Four revenue lines are on record. Investment Banking - PIPE and Registered Direct Offerings are the primary driver. The others are research Services, advisory Services and sales & Trading.

Who are H. C. Wainwright & Co.'s main competitors?

Direct peers on record are Maxim Group, Chardan Capital Markets, Lake Street Capital Markets, Aegis Capital Corp., Cantor Fitzgerald, Rodman & Renshaw and Roth Capital Partners. Emerging players are ThinkEquity and EF Hutton. B. Riley Financial is listed as a broad incumbent.

Does H. C. Wainwright & Co. have an API?

No public API is recorded for H. C. Wainwright & Co..

What industry is H. C. Wainwright & Co. in?

H. C. Wainwright & Co.'s product category is Investment Banking. Its primary akta.pro industry code is FSAEAGAJ, Industry-Specialist / Sector-Focused M&A Advisory, with a secondary code of FSAEACAG, Independent Broker-Dealer / Registered Representative Networks. Its NAICS code is 523 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. assumes coverage of Veritone at Buy, sets price target at $2HC Wainwright & Co. assumed coverage of Veritone at Buy and set a price target of $2. The target implies an upside of 454.2% from the Nov 17 close of $0.36.TradingViewHC Wainwright & Co. maintains Cerenome at Buy, raises price target to $7 from $1HC Wainwright & Co. maintained Cerenome at Buy and raised its price target to $7 from $1, a 600% increase. The target implies an upside of 1010.6% from the Nov 17 close of $0.63.TradingViewHC Wainwright & Co. maintains LifeMD at Buy, lowers price target to $6 from $9HC Wainwright & Co. maintained LifeMD at Buy and lowered its price target to $6 from $9, a 33.3% decrease. The target implies an upside of 234.3% from the Nov 17 close of $1.79.TradingViewHC Wainwright & Co. maintains uniQure at Buy, lowers price target to $65 from $80HC Wainwright & Co. maintained uniQure at Buy and lowered its price target to $65 from $80, an 18.8% decrease. The target implies an upside of 212.8% from the Nov 17 close of $20.78.TradingViewHC Wainwright & Co. maintains Solaris Resources at Buy, keeps price target at $18HC Wainwright & Co. maintained Solaris Resources at Buy and kept its price target at $18. The target implies an upside of 110% from the Nov 17 close of $8.57. The rating is not investment advice.TradingViewHC Wainwright & Co. maintains Prelude Therapeutics at Buy, keeps price target at $8HC Wainwright & Co. maintained Prelude Therapeutics at Buy with a price target of $8. The target implies a 141% upside from the Nov 17 close of $3.32. The firm's rating and target remain unchanged.TradingViewHC Wainwright & Co. maintains Fennec Pharmaceuticals at Buy, raises price target to $17 from $16HC Wainwright & Co. maintained Fennec Pharmaceuticals at Buy and raised its price target to $17 from $16, a 6.2% increase. The target implies a 25.2% upside from the Nov 17 close of $13.58.TradingViewHC Wainwright & Co. maintains Rein Therapeutics at Buy, keeps price target at $8HC Wainwright & Co. maintained Rein Therapeutics at Buy with a price target of $8. The target implies a 2144.7% upside from the Nov 17 close of $0.36. The rating is not investment advice.Quiver QuantitativeNew Analyst Forecast: $SLNH Given $3 Price Target | SLNH Stock NewsHC Wainwright & Co. analyst Mike Colonnese set a $3.0 price target for SLNH on 11/17/2026. The company reported Q2 2026 revenue of $15.1M, up 144.56% year-over-year. Insiders made 7 trades in the past six months, with 4 purchases and 3 sales.TradingViewHC Wainwright & Co. maintains Soluna Holdings at Buy, lowers price target to $3 from $3.50HC Wainwright & Co. maintained Soluna Holdings at Buy and lowered its price target to $3 from $3.50, a 14.3% decrease. The price target implies an upside of 556.3% from the Nov 16 close of $0.46.